OTCPK:PURE

Stock Analysis Report

Executive Summary

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally.


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has PURE Bioscience's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PURE's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-12.3%

PURE

1.3%

US Household Products

0.9%

US Market


1 Year Return

-7.5%

PURE

23.8%

US Household Products

20.0%

US Market

Return vs Industry: PURE underperformed the US Household Products industry which returned 25.4% over the past year.

Return vs Market: PURE underperformed the US Market which returned 20.1% over the past year.


Shareholder returns

PUREIndustryMarket
7 Day-12.3%1.3%0.9%
30 Day38.7%0.3%1.4%
90 Day65.3%3.9%8.8%
1 Year-7.5%-7.5%26.9%23.8%22.5%20.0%
3 Year-51.8%-51.8%47.1%35.0%49.9%40.3%
5 Year-33.9%-33.9%72.6%48.7%73.2%54.1%

Price Volatility Vs. Market

How volatile is PURE Bioscience's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is PURE Bioscience undervalued compared to its fair value and its price relative to the market?

25.42x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PURE's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PURE's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PURE is unprofitable, so we can't compare its PE Ratio to the Household Products industry average.

PE vs Market: PURE is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PURE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PURE is overvalued based on its PB Ratio (25.4x) compared to the US Household Products industry average (4x).


Next Steps

Future Growth

How is PURE Bioscience forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

12.5%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PURE Bioscience has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has PURE Bioscience performed over the past 5 years?

11.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PURE is currently unprofitable.

Growing Profit Margin: PURE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PURE is unprofitable, but has reduced losses over the past 5 years at a rate of 11.3% per year.

Accelerating Growth: Unable to compare PURE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PURE is unprofitable, making it difficult to compare its past year earnings growth to the Household Products industry (-14%).


Return on Equity

High ROE: PURE has a negative Return on Equity (-377.9%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is PURE Bioscience's financial position?


Financial Position Analysis

Short Term Liabilities: PURE's short term assets ($1.4M) exceed its short term liabilities ($877.0K).

Long Term Liabilities: PURE has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: PURE is debt free.

Reducing Debt: PURE had no debt 5 years ago.


Balance Sheet

Inventory Level: PURE has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if PURE's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PURE has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: PURE has less than a year of cash runway if free cash flow continues to grow at historical rates of 10.9% each year.


Next Steps

Dividend

What is PURE Bioscience's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.3%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate PURE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PURE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PURE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PURE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PURE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Tom Lee (70yo)

0.5yrs

Tenure

US$52,000

Compensation

Mr. Tom Y. Lee, CPA, is Chief Executive Officer of PURE Bioscience, Inc. since August 7, 2019 and has been its President since July 25, 2019. He serves as the Chairman and Chief Executive Officer of Swabpl ...


Leadership Team

NamePositionTenureCompensationOwnership
Tom Lee
CEO, President & Chairman0.5yrsUS$52.00k37.37% $12.9m
Mark Elliott
VP of Finance and Principal Financial & Accounting Officer4.6yrsUS$180.00k0.090% $31.1k
Thomas Myers
Chief Operating Officer1.3yrsUS$330.00k0.27% $94.1k
Bridget Tinsley-Cormier
Senior VP of Technology & Business Development and VP of Market Development3.5yrsno datano data

2.4yrs

Average Tenure

67yo

Average Age

Experienced Management: PURE's management team is considered experienced (2.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Tom Lee
CEO, President & Chairman0.5yrsUS$52.00k37.37% $12.9m
Thomas Thompson
Member of Advisory Panel10.4yrsUS$10.58kno data
Scott Russell
Member of Advisory Panel10.4yrsno datano data
Thomas Ridge
Member of Advisory Panel10.4yrsno datano data
Dale Okuno
Independent Director1.1yrsUS$78.00kno data
James Marsden
Member of Scientific Advisory Board3.9yrsno datano data
Robert Deibel
Member of the Advisory Panel8.8yrsno datano data
Elisabeth Hagen
Member of Scientific Advisory Board1.1yrsUS$51.25kno data
Janet Field
Member of Scientific Advisory Board1.1yrsUS$52.25kno data
Ivan Chen
Independent Director1.7yrsUS$52.00k0.24% $84.1k

2.8yrs

Average Tenure

67yo

Average Age

Experienced Board: PURE's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PURE insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.5%.


Top Shareholders

Company Information

PURE Bioscience, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PURE Bioscience, Inc.
  • Ticker: PURE
  • Exchange: OTCPK
  • Founded: 1992
  • Industry: Household Products
  • Sector: Household
  • Market Cap: US$34.390m
  • Shares outstanding: 79.99m
  • Website: https://www.purebio.com

Number of Employees


Location

  • PURE Bioscience, Inc.
  • 9669 Hermosa Avenue
  • Rancho Cucamonga
  • California
  • 91730
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PUREOTCPK (Pink Sheets LLC)YesClass A Common StockUSUSDAug 1996
IVMBBST (Boerse-Stuttgart)YesClass A Common StockDEEURAug 1996

Biography

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. It manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection and formulates with other compounds. The company offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate used to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate that is used to clean stainless steel equipment, resilient floors, walls, and painted surfaces. Its SDC-based disinfecting and sanitizing products comprise Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial solution that is used against bacteria, viruses, yeasts, and molds. The company was founded in 1992 and is headquartered in Rancho Cucamonga, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/17 23:39
End of Day Share Price2020/02/14 00:00
Earnings2019/10/31
Annual Earnings2019/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.